Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATM FOG
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ATM FOG refers to the use of atomoxetine for the treatment of freezing of gait (FOG) in Parkinson's disease. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) primarily approved for attention deficit hyperactivity disorder (ADHD), but it has been investigated off-label in clinical trials as a potential therapy to address gait disturbances, specifically freezing episodes, in patients with Parkinson's disease. The mechanism involves increasing synaptic concentrations of norepinephrine by inhibiting its reuptake, which may modulate motor and cognitive circuits implicated in Parkinsonian gait dysfunction[1].
- Brand names
- ATM FOG
- Other names
- ATM FOG
02
Targets
NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on ATM FOG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATM FOG.